Table 3.

Multivariate analysis results for progression-free survival and overall survival in non-small-cell lung cancer patients according to clinicopathologic characteristics.

	N		PFS						OS
			Univariate	Multivariate				Univariate	Multivariate
			p	HR		95%CI	p	p	HR	95%CI	p
All NSCLC patients
Gender (Female/Male)	104/62		0.03	1.25		0.87-1.82	0.23	0.44
Smoking (Never /Current or former)	91/75		0.35					0.02	2.34	1.33-4.09	0.003
Age at disease progression (≤60/>60)	66/100		0.20					0.07	1.72	0.94-3.15	0.08
EGOC PS at disease progression (EGOC 0-1/2-3)	138/28		<0.001	3.67		2.24-6.01	<0.001	<0.001	11.86	5.55-25.36	<0.001
Genotype (exon 19/21)	86/80		0.002	1.54		1.08-2.20	0.02	0.02	1.94	1.09-3.48	0.03
Brain metastases (No/Yes)	91/75		0.07					0.02	2.02	1.17-3.50	0.01
Patients with brain metastasis
Age at disease progression (≤60/>60)		31/44	0.34					0.004	3.38	1.35-8.47	0.009
EGOC PS at disease progression (EGOC 0-1/2-3)		60/15	<0.001	3.1	1.58-6.05		0.001	<0.001	5.59	2.34-13.36	<0.001
Genotype (exon 19/21)		38/37	<0.001	2.60	1.51-4.48		0.001	0.006	2.67	1.17-6.05	0.02
Patients with bone metastasis
Gender (Female/Male)		48/28	0.01	2.07	1.16-3.73		0.02	0.80
Smoking (Never /Current or former)		45/31	0.005	1.75	0.96-3.19		0.07	0.02	1.99	0.77-5.13	0.16
EGOC PS at disease progression (EGOC 0-1/2-3)		65/11	0.002	2.83	1.30-6.19		0.009	<0.001	7.79	2.52-24.09	<0.001
Number of bone metastasis (<1/>1)		15/61	0.03	1.69	0.82-3.50		0.16	0.004	4.29	0.850-21.72	0.08

Abbreviations: NSCLC, non-small-cell lung cancer; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, The disease-free survival; OS, the overall survival.